Sage Therapeutics, Inc. (SAGE)

Sage Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative medicines to treat central nervous system (CNS) disorders. Founded in 2010 and headquartered in Cambridge, Massachusetts, Sage is dedicated to transforming the lives of patients with serious and life-altering CNS conditions. The company's pioneering work includes groundbreaking treatments in neurology and psychiatry, with a strong emphasis on areas like depression and neuropsychiatric disorders. As of 2023, Barry Greene, a seasoned leader with extensive experience in the biotech industry, serves as the CEO. Sage Therapeutics has made headlines with products such as Zulresso (brexanolone), the first treatment specifically approved for postpartum depression. As a publicly traded company on the NASDAQ under the ticker SAGE, Sage Therapeutics reported significant revenues as it continues to advance its pipeline and expand its impact in CNS therapies.